《关于公司股票被实施其他风险警示相关事项的进展公告》 《2026年第一次临时股东会的法律意见书》 《关于2026年第一次临时股东会决议的公告》 近日，ST百灵发布《关于公司股票被实施其他风险警示相关事项的进展公告》。公告显示，公司于 2025年12月19日收到贵州证监局出具的《行政处罚事先告知书》，因公司披露的2019年、2020年、2021 年、2023年年报存在虚假记载，公司股票自2025年12月23日起被实施其他风险警示。公司已组织财务部 门及年审会计师事务所对相关年度财务会计报告进行核查，差错更正及追溯调整工作正在推进中。公司 董事会将持续完善内控体系，加强合规培训。截至公告披露日，公司生产经营正常，最终处罚结果以证 监会正式决定书为准。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 截至2026年2月24日收盘，ST百灵（002424）报收于4.45元，较前一交易日上涨2.06%，最新总市值为 62.19亿元。该股当日开盘4.39元，最高4.57元，最低4.37元，成交额达1.17亿元，换手率为2.15%。 最新公告列表 ...

Core Viewpoint - The company held its first extraordinary general meeting of shareholders in 2026, where no proposals were rejected, and the meeting adhered to legal and regulatory requirements [1][2][3] Meeting Details - The meeting took place on February 13, 2026, with both on-site and online voting options available [2][3] - A total of 621 shareholders attended, representing 270,926,194 shares, which is 19.3851% of the total voting shares [4] - The meeting was chaired by the company's chairman, Jiang Wei, and was legally witnessed by lawyers from Guizhou Beidouxing Law Firm [3][10] Voting Results - Proposal 1, concerning the company's guarantee for a loan application by its subsidiary, was approved with 264,003,921 votes in favor, accounting for 97.4450% of the valid votes [11][12] - Among minority shareholders, 18,158,737 votes were in favor, representing 72.4003% of their valid votes [13] Legal Opinions - The lawyers confirmed that the meeting's procedures and voting were in compliance with relevant laws and regulations, deeming the results valid [14] Risk Warning and Progress Update - The company is under risk warning due to previous disclosures of false information in annual reports from 2019 to 2021 and 2023, as indicated by the administrative penalty notice received from the Guizhou Securities Regulatory Bureau [17][18] - The company is actively addressing the issues raised, including conducting further audits and enhancing internal control measures [18]

证券代码：002424 证券简称：ST 百灵 公告编号：2026-010 贵州百灵企业集团制药股份有限公司 2、根据《深圳证券交易所股票上市规则（2025 年修订）》第 9.8.6 条规定，公司因触及第 9.8.1 条第八项情形，其股票交易被实施其 他风险警示期间，应当至少每月披露一次差错更正进展公告，直至披 露行政处罚决定所涉事项财务会计报告更正公告及会计师事务所出 具的专项核查意见等文件。 一、实施其他风险警示的原因 公司于 2025 年 12 月 19 日收到贵州证监局出具的《行政处罚事 先告知书》（黔处罚字[2025]1 号）。根据《行政处罚事先告知书》的 认定的情况，公司披露的 2019 年、2020 年、2021 年、2023 年年报 存在虚假记载。根据《深圳证券交易所股票上市规则（2025 年修订）》 第 9.8.1 条第八项规定，公司股票于 2025 年 12 月 23 日开市起被 实施其他风险警示。具体内容详见公司于 2025 年 12 月 20 日在指定 信息披露媒体《证券时报》《证券日报》《中国证券报》《上海证券报》 和巨潮资讯网（www.cninfo.com.cn）披露的《关于公司及相 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决提案的情形。 2、本次股东会未涉及变更以往股东会已通过的决议。 证券代码：002424 证券简称：ST 百灵 公告编号：2026-009 贵州百灵企业集团制药股份有限公司 关于 2026 年第一次临时股东会决议的公告 一、会议召开和出席情况 （一）会议召开情况 1、召开时间： 现场会议召开时间：2026年2月13日（星期五）上午十时 网络投票时间：通过深圳证券交易所交易系统进行网络投票的具 体时间为 2026 年 2 月 13 日（现场股东会召开当日）的交易时间，即 9:15—9:25,9:30—11:30 和 13:00—15:00。通过深圳证券交易所互 联网投票系统进行网络投票的开始时间为 2026 年 2 月 13 日（现场股 东会召开当日）9:15，结束时间为 2026 年 2 月 13 日（现场股东会结 束当日）15:00。 2、召开地点：贵州省安顺市经济技术开发区西航路 212 号贵州 百灵企业集团制药股份有限公司会议室 3、召开方式：现场投票和网络投票相结合的方式 ...

贵州北斗星律师事务所法律意见书 一、本次股东会的召集和召开程序 (一)本次股东会由公司董事会（以下简称"董事会"）负责召集。董 事会于 2026 年 1 月 29 日公告了《贵州百灵企业集团制药股份有限公司关 于召开 2026 年第一次临时股东会通知的公告》（公告编号:2026-004）。 根据公告的通知，公司董事会提请本次股东会审议的事项为： 致：贵州百灵企业集团制药股份有限公司 贵州北斗星律师事务所(以下简称"本所")接受贵州百灵企业集团制 药股份有限公司（以下简称"公司"）委托，指派本所律师郑锡国、张妮 出席了公司于 2026 年 2 月 13 日上午 10：00 在贵州省安顺市经济技术开发 区西航路 212 号贵州百灵企业集团制药股份有限公司会议室召开的公司 2026 年第一次临时股东会（以下简称"本次股东会"）。现根据《中华人 民共和国公司法》、《中华人民共和国证券法》等有关法律、法规及规章 和《贵州百灵企业集团制药股份有限公司章程》（以下简称（"公司章程"）、 《贵州百灵企业集团制药股份有限公司股东大会议事规则》（以下简称"议 事规则"）的规定，出具本法律意见书。 关于贵州百灵企业集团制药股份有限 ...

Core Viewpoint - Guizhou BaiLing Pharmaceutical Group Co., Ltd. (ST BaiLing) is facing significant challenges, including a projected net loss for 2025, regulatory penalties, and ongoing litigation, raising concerns about its future prospects [3][4][11]. Financial Performance and Compliance Challenges - The company expects a net profit loss of between 60 million to 90 million yuan for 2025, attributing this to a 20% year-on-year decline in revenue and increased fixed costs due to expanded fixed asset scale [4][5][16]. - In 2023, the company reported a loss of 416 million yuan and received a negative internal control audit report from Tianjian Accounting Firm [4][15]. - ST BaiLing was placed under risk warning and its stock was renamed due to the negative audit report, which highlighted significant internal control deficiencies related to sales expense reporting [5][15]. Regulatory Issues - The company was investigated by the China Securities Regulatory Commission (CSRC) for information disclosure violations, leading to a pre-penalty notice from the Guizhou Securities Regulatory Bureau in December 2025 [6][16]. - A fine of 10 million yuan was imposed on the company, with the former chairman and other responsible parties fined a total of 25.6 million yuan [6][17]. Share Pledge and Litigation - The company's controlling shareholder, Jiang Wei, has fully pledged 17.55% of his shares, with a 60% decline in stock price since the pledge [7][18]. - A significant lawsuit with Huachuang Securities involves a total claim of 1.761 billion yuan, stemming from a 2019 rescue plan and stock pledge agreements that Jiang Wei failed to fulfill [8][19]. Market Position and Industry Challenges - Once a leader in the herbal medicine sector, ST BaiLing has struggled with declining sales of core products due to factors such as healthcare cost control, intensified competition in the generic drug market, and lagging innovation [10][21]. - Previous investments in GAP planting bases and diabetes hospitals have not yielded expected returns, further impacting overall performance [10][21].

Core Viewpoint - ST Bailing (002424) expects a significant decline in net profit attributable to shareholders for the fiscal year 2025, projecting a loss between 60 million to 90 million yuan, representing a year-on-year decrease of 278.46% to 367.68% [1] Group 1: Financial Performance - The company anticipates a revenue decline of approximately 20% year-on-year for 2025 due to factors such as slowing product market demand, adjustments in medical insurance payment policies, and intensified market competition [1] - The increase in fixed asset scale has led to higher depreciation and amortization expenses, contributing to the overall rise in fixed costs and negatively impacting the net profit attributable to shareholders [1] Group 2: Strategic Response - Despite facing challenges from industry cyclical fluctuations, the company plans to continue pursuing its strategic development goals to adapt to the complex and changing environment of the pharmaceutical industry [1] - The company aims to expand market sales of its leading products and optimize its product structure to increase market share [1] - Continuous investment in research and development projects is planned to enrich the product pipeline and accelerate the market launch of new projects [1] - The company will enhance compliance management to effectively reduce various risks [1] Group 3: Management Confidence - The management team expresses confidence in the company's future operational development, committing to cost reduction and efficiency improvement initiatives to enhance operational quality and product competitiveness [2] - The focus will be on improving business performance and promoting sustainable development [2]

Core Viewpoint - ST Bailing (002424) is expected to report significant losses for the year 2025, with net profit forecasts indicating a decline of up to 367.68% compared to the previous year [1][3]. Trading Information Summary - On January 30, ST Bailing's stock closed at 4.23 yuan, with a turnover rate of 1.18% and a trading volume of 143,100 hands, resulting in a transaction amount of 60.4362 million yuan [1]. - The net inflow of main funds was 5.93 million yuan, while retail funds saw a net inflow of 0.2137 million yuan, indicating mixed investor sentiment [1][3]. Performance Disclosure Highlights - ST Bailing forecasts a net profit loss for 2025 ranging from 60 million yuan to 90 million yuan, with a year-on-year decline of 278.46% to 367.68% [1][3]. - The company also anticipates a non-recurring net profit loss between 102 million yuan and 132 million yuan, reflecting a year-on-year decrease of 23.73% to 60.13% [1][3]. - The expected basic earnings per share for 2025 is projected to be between -0.04 yuan and -0.07 yuan [1]. Company Announcement Summary - The decline in ST Bailing's performance is attributed to multiple factors, including a slowdown in market demand, adjustments in medical insurance payment policies, intensified market competition, and rising fixed costs [1][3].

Group 1 - The company expects a negative net profit for the fiscal year 2025, with a projected revenue decline of approximately 20% year-on-year due to factors such as reduced market demand, adjustments in medical insurance payment policies, and intensified market competition [1] - The company has communicated with its auditing firm regarding the performance forecast, and there are no significant discrepancies in the financial data discussed [1] - The increase in fixed asset scale has led to higher depreciation and amortization expenses, contributing to the decline in net profit attributable to shareholders [1] Group 2 - In 2026, the company aims to continue its development strategy despite facing challenges from industry cyclical fluctuations, focusing on expanding market sales of leading products and optimizing product structure [2] - The company plans to invest continuously in research and development projects to enrich its product pipeline and accelerate the launch of new projects [2] - Management expresses confidence in improving operational quality and enhancing product competitiveness to promote sustainable development [2]

Core Viewpoint - Guizhou Bailing (ST Bailing) expects a negative net profit for the fiscal year 2025 due to various factors including a slowdown in product market demand, adjustments in medical insurance payment policies, and intensified market competition [1] Group 1: Company Performance and Challenges - The overall business of Guizhou Bailing remains stable, but the company faces pressure on profits due to changes in supply and demand across the industry chain, inventory pressures, and increased fixed costs from expanded fixed asset scale and depreciation expenses [1] - In 2025, the pharmaceutical manufacturing industry in China reported a revenue of 2.49 trillion yuan, a year-on-year decline of 1.2% [1] - Over half of the more than 20 listed traditional Chinese medicine companies that have disclosed their 2025 performance forecasts are expected to incur losses [1] Group 2: Product and Market Strategy - Guizhou Bailing has ranked among the top non-prescription drug companies in China for ten consecutive years, with 14 products making it to various product rankings, achieving a historical high in the number of products listed [2] - The core product, Yindan Xinnaotong soft capsules, has maintained positive sales growth since 2019 and is expected to benefit from the expanding "silver economy" [2] - The company has completed direct sales reform in 15 provinces and is exploring diverse international market paths, with six products registered in countries like Turkmenistan, Brazil, and Singapore [2] Group 3: Future Outlook and Strategic Initiatives - For 2026, the company plans to expand market sales of its leading products and optimize product structure to increase market share, while also investing in R&D to enrich its product pipeline and accelerate the pace of project launches [3] - The management expresses confidence in improving operational quality and product competitiveness through cost reduction and efficiency enhancement efforts [3] - Industry experts note that Guizhou Bailing is currently in a phase of "valuation bottom + performance inflection point + long-term growth," with potential for long-term value consolidation as industry recovery signals emerge [3]